Fakultni Nemocnice Brno

Running trials

• Active, not recruiting

  An open-label study to collect safety and effectiveness information on long-term treatment with vamorolone in boys with Duchenne Muscular Dystrophy who have completed prior studies with vamorolone (The GUARDIAN Study)

  2024-512828-12-00· Phase 4· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Source

• Recruiting

  A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

  NCT05748171· Phase 2· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Source

• Active, not recruiting

  A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

  NCT03591510· Phase 2· Source

• Recruiting

  Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

  NCT03643276· Phase 3· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Source

• Active, not recruiting

  International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

  NCT02066220· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Neuroblastoma1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· Source

• Active, not recruiting

  A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

  NCT05970172· Phase 3· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

  NCT05562466· Phase 3· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Source

• Active, not recruiting

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· Phase 1· Source

• Completed

  Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours

  2024-511071-16-00· Phase 1· Source

• Completed

  A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

  NCT04447755· Phase 2· Source

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Source